Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,970,294

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up

Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.

Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down

Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.

Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.

Stryker's (SYK) Q4 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs adversely impact margins.

Sweta Killa headshot

5 Top Dividend Growth Stocks to Buy in the Month of Love

Archer-Daniels (ADM), Agilent Technologies (A), Republic Services (RSG), Deere & Company (DE) and Cardinal Health (CAH) seem solid picks for this month.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

Ongoing sales rebound in the base business for the Diagnostics and Drug Development segments likely drive LabCorp (LH) Q4 revenues.

Integer Holdings (ITGR) Announces Solid Preliminary Q4 Revenues

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls

ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.

Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.

McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

What's in the Cards for Illumina (ILMN) in Q4 Earnings?

Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.

CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?

CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Buy Cardinal Health (CAH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.